1.1Loading from a nonzero concentration
The cornea enters a chamber prefilled with a solution at 20% of the target concentration. Two metering pumps shift the inlet mixture toward a concentrated stock until the chamber reaches the target.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The cornea enters a chamber prefilled with a solution at 20% of the target concentration. Two metering pumps shift the inlet mixture toward a concentrated stock until the chamber reaches the target.
A selector valve connects the chamber to reservoirs at successively higher concentrations. A drain and fill cycle exchanges the bath at each step, and a timer holds the cornea in each bath before the next exchange.
A perforated carrier grips the tissue at its peripheral rim and leaves both corneal surfaces exposed to solution. A motorized arm lifts the carrier, lets it drain briefly, and lowers it into the next bath in the concentration series.
A jacketed chamber holds the solution at a fixed chilled temperature while metering pumps increase the cryoprotectant concentration over 40 minutes. A refractometer calibrated for the formulation and temperature verifies the final bath concentration.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary research laboratory mounts porcine corneas from an abattoir in individual flow cells for later ex vivo testing. Each cell holds the outer scleral rim and directs mixed cryoprotectant solution across both exposed faces while the cornea stays fixed. The cell drains before the holder transfers to a cryogenic storage cassette, and the rewarmed cornea goes into a pressure chamber for measurement of corneal swelling.
Four spring clips on a removable frame replace the suspension ring and grip the outer scleral rim. The frame locks into slots in a flow cell, holding the cornea clear of the chamber walls and leaving both faces exposed. A premixed stream enters through a low inlet and exits through a high outlet as the cryoprotectant concentration rises.
Six 2 mL flow cells each hold one cornea and receive the same concentration ramp from a common mixer. A six-port manifold feeds equal lengths of tubing with matched flow restrictors, and each cell receives 2 mL per minute. Each cell has a separate drain so outlet flow can be checked before loading begins.
A drainable flow cell mounts on the sample shelf of a programmable liquid nitrogen vapor freezer. External pumps deliver the concentration ramp through tubing that enters the chamber through a service port. After loading, the cell drains and isolation valves close at the chamber wall. The freezer then controls vapor flow around the cell using a temperature probe beside the corneal holder.
Two metering pumps feed cryoprotectant stock and carrier solution into a static mixer, and an inline refractometer sits between the mixer and the corneal chamber. A controller uses a temperature-corrected calibration for the selected formulation to convert refractive index to concentration. It adjusts the ratio of the two pump rates to track a programmed ramp while keeping their combined flow constant.
An optical coherence tomography probe measures central corneal thickness through a clear chamber window while a fixed holder keeps the cornea aligned. Software tracks thickness from successive depth scans and compares its rate of change with a programmed limit. The controller reduces the slope of the concentration ramp when thinning exceeds the limit and restores the programmed slope when thinning slows. It ends the ramp when an inlet concentration sensor registers the target concentration.
A carrier lifts the cornea from the bath and drains the bulk liquid while retaining a thin surface film. A chamber with controlled humidity removes water from that film, and optical refractometry tracks the increase in cryoprotectant concentration before cooling.
Two syringe pumps feed a static mixer from base solution and concentrated stock at a constant combined flow. A controller changes the flow ratio continuously over 20 minutes, and the mixed stream passes over the stationary cornea.
A recirculation loop withdraws solution from a fixed-volume chamber and returns it through a diffuser beside the stationary cornea. A metering pump adds concentrated stock upstream of the diffuser while an overflow maintains chamber volume, and an inline refractometer tracks the continuous rise to the target concentration.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Next, several rabbit kidneys were perfused in an LM5 carrier solution with concentrations of cryoprotectants that are sufficient to vitrify at ambient pressures. Calcium and magnesium were gradually removed and added back as cryoprotectant concentrations were increased and then reduced, in order to avoid precipitation of these ions.A · US 2005/0153272 A1 · ¶ 30
R0250) at an undiluted stock concentration of 18% v/v; where cryoprotectants were diluted with the buffer medium at a volumetric ratio of 1:2 to obtain a 6.6% glycerol and 6% raffinose concentration, and (c) 0.25 mL of liquefied sperm was immediately mixed with 0.25 mL of the vitrification medium (at a ratio of 1:1 v/v) until a final glycerol concentration of 3.3% and a final raffinose concentration of 3% was obtained;B · US 2021/0186007 A1 · ¶ 37
An empty cell means only that no passage was reproduced there.
This lack of a suitable carrier solution is a major impediment to applying vitrification to whole organs and engineered systems.A · US 2005/0153272 A1 · ¶ 5
It is a further object to provide a carrier solution that gives excellent results when used both with isolated tissue slices and with whole organs and for a variety of newer-generation vitrification solutions.A · US 2005/0153272 A1 · ¶ 6
This invention provides a simple, fast and effective sperm vitrification method which allows a recovery of progressive sperm motility after devitrification of 80 to 95%, whether in samples from normozoospermic patients or oligospermic patients and/or patients with other alterations in the seminal parameters.B · US 2021/0186007 A1 · ¶ 6
The invention can be applied to the vitrification of donor sperm samples in sperm banks as well as patient samples to be used later in assisted reproduction cycles.B · US 2021/0186007 A1 · ¶ 6
patent.fyi, US 2026/0354371 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354371/, SHA-256 10c93b25769ddeffbe21038dd7860d71fd80ac94a695d19ecddb8e977f207deb